<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664466</url>
  </required_header>
  <id_info>
    <org_study_id>AXE OA PAIN</org_study_id>
    <nct_id>NCT03664466</nct_id>
  </id_info>
  <brief_title>Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators</brief_title>
  <acronym>AXE OA PAIN</acronym>
  <official_title>Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Luke's Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Luke's Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to assess the effects of astaxanthin use on pain, physical function,
      and inflammation as reflected by Patient-Reported Outcomes Measurement Information System
      (PROMIS) scores and levels of inflammatory biomarkers in subjects taking astaxanthin. If
      improvements in pain, function, and/or markers of inflammation could be demonstrated with the
      use of astaxanthin, this may suggest the potential for astaxanthin to be used in management
      of knee osteoarthritis (and possibly other forms of osteoarthritis) with less evident
      toxicity than seen with the presently available standard therapies (e.g. NSAIDS, opioids).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PROMIS Numeric Rating Pain Scale</measure>
    <time_frame>20 weeks</time_frame>
    <description>Pain improvement in subjects is the primary outcome measure. The Patient Reported Outcomes Measurement Information Systems (PROMIS) Pain Intensity Scale 1a tool will be used. This scale ranges from 0-10, with 0 representing no pain and 10 representing the worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Pain interference score</measure>
    <time_frame>20 weeks</time_frame>
    <description>Reduction in pain interference is a secondary outcome measure. The Patient Reported Outcomes Measurement Information Systems (PROMIS) Pain Interference Short Form 6b will be used as the survey tool for pain interference. This is a set of 6 questions to assess the degree to which pain has interfered with daily activities. There are 5 levels of pain interference from 0 (none at all) to 5 (very much or always). The higher the score, the greater the pain interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Physical function score</measure>
    <time_frame>20 weeks</time_frame>
    <description>Improvement in physical function is a secondary outcome measure. The PROMIS Physical Function Short Form 6b will be used as the survey tool for physical limitation. There are 5 levels of limitation to physical function from 0 (without any difficulty) to 5 (unable to do). The higher the score, the greater the limitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erythrocyte Sedimentation Rate</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in ESR (mm/hr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein levels</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in CRP levels (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-6 levels</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in IL-6 levels (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cartilage Oligomeric Matrix Protein levels</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in COMP levels (ng/mL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Astaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Astaxanthin 12mg twice daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>astaxanthin</intervention_name>
    <description>astaxanthin capsules 12 mg twice daily</description>
    <arm_group_label>Astaxanthin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Symptoms of knee pain

          -  Radiographic evidence of mild to moderate arthritis

          -  Able to provide written consent on their own behalf

        Exclusion Criteria:

          -  Pregnancy

          -  Current tobacco use

          -  Current substance abuse (alcohol or drug)

          -  Presence of significant cardiovascular, pulmonary, hepatic, or renal disease

          -  Prior history of knee trauma or surgery

          -  Gout or pseudogout

          -  Significant depression or anxiety scores on PHQ-9 and GAD-7, or pre-existing diagnosis
             of a significant mental health disorder

          -  Presence of other chronic pain syndromes such as chronic low back or neck pain,
             fibromyalgia, or complex regional pain syndrome

          -  Presence of systemic inflammatory conditions such as rheumatoid arthritis, systemic
             lupus erythematosus, inflammatory bowel disease

          -  Symptomatic involvement of multiple other joints with osteoarthritis

          -  Known allergy to fish or astaxanthin

          -  BMI greater than 35

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Elliott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Luke's Hospital of Kansas City</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Elliott, MD</last_name>
    <phone>816-932-2932</phone>
    <email>jelliott@saintlukeskc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aaron Heller, DO</last_name>
    <phone>317-796-6393</phone>
    <email>helleran@umkc.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986 Aug;29(8):1039-49.</citation>
    <PMID>3741515</PMID>
  </reference>
  <reference>
    <citation>Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013 Apr;5(2):77-94. doi: 10.1177/1759720X12467868.</citation>
    <PMID>23641259</PMID>
  </reference>
  <reference>
    <citation>Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin F, Hill CL, Laslett LL, Jones G, Cicuttini F, Osborne R, Vos T, Buchbinder R, Woolf A, March L. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763. Epub 2014 Feb 19.</citation>
    <PMID>24553908</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):421-6.</citation>
    <PMID>19407734</PMID>
  </reference>
  <reference>
    <citation>Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs. 2012 Mar;112(3 Suppl 1):S13-9. doi: 10.1097/01.NAJ.0000412646.80054.21. Review.</citation>
    <PMID>22373741</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States, 2003. MMWR Morb Mortal Wkly Rep. 2007 Jan 12;56(1):4-7.</citation>
    <PMID>17218935</PMID>
  </reference>
  <reference>
    <citation>Hochberg MC. Mortality in osteoarthritis. Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S120-4. Review.</citation>
    <PMID>19026154</PMID>
  </reference>
  <reference>
    <citation>Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.</citation>
    <PMID>23726390</PMID>
  </reference>
  <reference>
    <citation>National Center for Health Statistics (US). Health, United States, 2014: With Special Feature on Adults Aged 55–64. Hyattsville (MD): National Center for Health Statistics (US); 2015 May.</citation>
    <PMID>26086064</PMID>
  </reference>
  <reference>
    <citation>CDC. Multiple cause of death data on CDC WONDER. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. http://wonder.cdc.gov/mcd.html</citation>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1487-92.</citation>
    <PMID>22048730</PMID>
  </reference>
  <reference>
    <citation>Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. doi: 10.15585/mmwr.rr6501e1. Erratum in: MMWR Recomm Rep. 2016;65(11):295.</citation>
    <PMID>26987082</PMID>
  </reference>
  <reference>
    <citation>Le Graverand-Gastineau MP. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets. 2010 May;11(5):528-35. Review.</citation>
    <PMID>20199396</PMID>
  </reference>
  <reference>
    <citation>Astaxanthin as a pigmenter in salmon feed. Chemicals HVF. Hoffman-La Roche Inc., 1987.</citation>
  </reference>
  <reference>
    <citation>Higuera-Ciapara I, Félix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006;46(2):185-96. Review.</citation>
    <PMID>16431409</PMID>
  </reference>
  <reference>
    <citation>Spiller GA, Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food. 2003 Spring;6(1):51-6.</citation>
    <PMID>12804020</PMID>
  </reference>
  <reference>
    <citation>Okada Y, Ishikura M, Maoka T. Bioavailability of astaxanthin in Haematococcus algal extract: the effects of timing of diet and smoking habits. Biosci Biotechnol Biochem. 2009 Sep;73(9):1928-32. Epub 2009 Sep 7.</citation>
    <PMID>19734684</PMID>
  </reference>
  <reference>
    <citation>Mercke Odeberg J, Lignell A, Pettersson A, Höglund P. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci. 2003 Jul;19(4):299-304.</citation>
    <PMID>12885395</PMID>
  </reference>
  <reference>
    <citation>Yoshida H, Yanai H, Ito K, Tomono Y, Koikeda T, Tsukahara H, Tada N. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis. 2010 Apr;209(2):520-3. doi: 10.1016/j.atherosclerosis.2009.10.012. Epub 2009 Oct 14.</citation>
    <PMID>19892350</PMID>
  </reference>
  <reference>
    <citation>Miyawaki H, Takahashi J, Tsukahara H, Takehara I. Effects of astaxanthin on human blood rheology. J Clin Biochem Nutr. 2008 Sep;43(2):69-74. doi: 10.3164/jcbn.2008048.</citation>
    <PMID>18818755</PMID>
  </reference>
  <reference>
    <citation>Iwabayashi M et al., Efficacy and safety of eight-week treatment with astaxanthin in individuals screened for increased oxidative stress burden. Anti-aging medicine. 2009;6(4):15-21.</citation>
  </reference>
  <reference>
    <citation>Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008 May 22;101(10A):58D-68D. doi: 10.1016/j.amjcard.2008.02.010. Review.</citation>
    <PMID>18474276</PMID>
  </reference>
  <reference>
    <citation>Hussein G, Nakagawa T, Goto H, Shimada Y, Matsumoto K, Sankawa U, Watanabe H. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci. 2007 Jan 16;80(6):522-9. Epub 2006 Oct 12.</citation>
    <PMID>17074368</PMID>
  </reference>
  <reference>
    <citation>Kim KY et al., The effects of astaxanthin supplements on lipid peroxidation and antioxidant status in postmenopausal women. Nutritional Sciences. 2004;7(1):41-46.</citation>
  </reference>
  <reference>
    <citation>Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, Lee SK, Kim YM. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells. 2003 Aug 31;16(1):97-105.</citation>
    <PMID>14503852</PMID>
  </reference>
  <reference>
    <citation>Lu YP, Liu SY, Sun H, Wu XM, Li JJ, Zhu L. Neuroprotective effect of astaxanthin on H(2)O(2)-induced neurotoxicity in vitro and on focal cerebral ischemia in vivo. Brain Res. 2010 Nov 11;1360:40-8. doi: 10.1016/j.brainres.2010.09.016. Epub 2010 Sep 21.</citation>
    <PMID>20846510</PMID>
  </reference>
  <reference>
    <citation>Hussein G, Goto H, Oda S, Iguchi T, Sankawa U, Matsumoto K, Watanabe H. Antihypertensive potential and mechanism of action of astaxanthin: II. Vascular reactivity and hemorheology in spontaneously hypertensive rats. Biol Pharm Bull. 2005 Jun;28(6):967-71.</citation>
    <PMID>15930728</PMID>
  </reference>
  <reference>
    <citation>Lee DH, Kim CS, Lee YJ. Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol. 2011 Jan;49(1):271-80. doi: 10.1016/j.fct.2010.10.029. Epub 2010 Nov 5.</citation>
    <PMID>21056612</PMID>
  </reference>
  <reference>
    <citation>Haines DD, Varga B, Bak I, Juhasz B, Mahmoud FF, Kalantari H, Gesztelyi R, Lekli I, Czompa A, Tosaki A. Summative interaction between astaxanthin, Ginkgo biloba extract (EGb761) and vitamin C in suppression of respiratory inflammation: a comparison with ibuprofen. Phytother Res. 2011 Jan;25(1):128-36. doi: 10.1002/ptr.3160.</citation>
    <PMID>20632299</PMID>
  </reference>
  <reference>
    <citation>KELLGREN JH, LAWRENCE JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957 Dec;16(4):494-502.</citation>
    <PMID>13498604</PMID>
  </reference>
  <reference>
    <citation>Verma P, Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker. J Orthop Res. 2013 Jul;31(7):999-1006. doi: 10.1002/jor.22324. Epub 2013 Feb 19.</citation>
    <PMID>23423905</PMID>
  </reference>
  <reference>
    <citation>Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, Pepys MB. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 1997 Apr;40(4):723-7.</citation>
    <PMID>9125256</PMID>
  </reference>
  <reference>
    <citation>Tseng S, Reddi AH, Di Cesare PE. Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis. Biomark Insights. 2009 Feb 17;4:33-44.</citation>
    <PMID>19652761</PMID>
  </reference>
  <reference>
    <citation>Attur M, Krasnokutsky-Samuels S, Samuels J, Abramson SB. Prognostic biomarkers in osteoarthritis. Curr Opin Rheumatol. 2013 Jan;25(1):136-44. doi: 10.1097/BOR.0b013e32835a9381. Review.</citation>
    <PMID>23169101</PMID>
  </reference>
  <reference>
    <citation>Crane EH. Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013-.</citation>
    <PMID>27631059</PMID>
  </reference>
  <reference>
    <citation>Bruyere O, Honore A, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster JY. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage. 2003 Jan;11(1):1-5.</citation>
    <PMID>12505481</PMID>
  </reference>
  <reference>
    <citation>Jin X, Jones G, Cicuttini F, Wluka A, Zhu Z, Han W, Antony B, Wang X, Winzenberg T, Blizzard L, Ding C. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2016 Mar 8;315(10):1005-13. doi: 10.1001/jama.2016.1961.</citation>
    <PMID>26954409</PMID>
  </reference>
  <reference>
    <citation>Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ; Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA. 2002 Jan 2;287(1):64-71. Erratum in: JAMA 2002 Feb 27;287(8):989.</citation>
    <PMID>11754710</PMID>
  </reference>
  <reference>
    <citation>Bellamy N. The WOMAC Knee and Hip Osteoarthritis Indices: development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S148-53.</citation>
    <PMID>16273799</PMID>
  </reference>
  <reference>
    <citation>Schumacher HR, Pullman-Mooar S, Gupta SR, Dinnella JE, Kim R, McHugh MP. Randomized double-blind crossover study of the efficacy of a tart cherry juice blend in treatment of osteoarthritis (OA) of the knee. Osteoarthritis Cartilage. 2013 Aug;21(8):1035-41. doi: 10.1016/j.joca.2013.05.009. Epub 2013 May 31.</citation>
    <PMID>23727631</PMID>
  </reference>
  <reference>
    <citation>Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, Fort JG. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. Epub 2004 Apr 13.</citation>
    <PMID>15082468</PMID>
  </reference>
  <reference>
    <citation>McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum. 2001 Oct;45(5):453-61.</citation>
    <PMID>11642645</PMID>
  </reference>
  <reference>
    <citation>Augusti PR, Quatrin A, Somacal S, Conterato GM, Sobieski R, Ruviaro AR, Maurer LH, Duarte MM, Roehrs M, Emanuelli T. Astaxanthin prevents changes in the activities of thioredoxin reductase and paraoxonase in hypercholesterolemic rabbits. J Clin Biochem Nutr. 2012 Jul;51(1):42-9. doi: 10.3164/jcbn.11-74. Epub 2012 Jun 8.</citation>
    <PMID>22798712</PMID>
  </reference>
  <reference>
    <citation>Choi HD, Kim JH, Chang MJ, Kyu-Youn Y, Shin WG. Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother Res. 2011 Dec;25(12):1813-8. doi: 10.1002/ptr.3494. Epub 2011 Apr 8.</citation>
    <PMID>21480416</PMID>
  </reference>
  <reference>
    <citation>Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012 Aug;51(2):249-57. doi: 10.1016/j.bone.2012.02.012. Epub 2012 Feb 22. Review.</citation>
    <PMID>22387238</PMID>
  </reference>
  <reference>
    <citation>Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014 Dec;70(2):185-93. doi: 10.1016/j.cyto.2014.06.019. Epub 2014 Jul 24. Review.</citation>
    <PMID>25066335</PMID>
  </reference>
  <reference>
    <citation>Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011 Sep;23(5):471-8. doi: 10.1097/BOR.0b013e328349c2b1. Review.</citation>
    <PMID>21788902</PMID>
  </reference>
  <reference>
    <citation>Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010 Mar;62(3):647-57. doi: 10.1002/art.27290. Review.</citation>
    <PMID>20187160</PMID>
  </reference>
  <reference>
    <citation>Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010 Nov;6(11):625-35. doi: 10.1038/nrrheum.2010.159. Epub 2010 Oct 5. Review.</citation>
    <PMID>20924410</PMID>
  </reference>
  <reference>
    <citation>Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013 Jan;21(1):16-21. doi: 10.1016/j.joca.2012.11.012. Epub 2012 Nov 27. Review.</citation>
    <PMID>23194896</PMID>
  </reference>
  <reference>
    <citation>Malemud CJ. Biologic basis of osteoarthritis: state of the evidence. Curr Opin Rheumatol. 2015 May;27(3):289-94. doi: 10.1097/BOR.0000000000000162. Review.</citation>
    <PMID>25784380</PMID>
  </reference>
  <reference>
    <citation>Rahmati M, Mobasheri A, Mozafari M. Inflammatory mediators in osteoarthritis: A critical review of the state-of-the-art, current prospects, and future challenges. Bone. 2016 Apr;85:81-90. doi: 10.1016/j.bone.2016.01.019. Epub 2016 Jan 23. Review.</citation>
    <PMID>26812612</PMID>
  </reference>
  <reference>
    <citation>Singh S, Shahi NT, Shahi U, Kumar D. Serum Cartilage Oligomeric Matrix Protein (COMP) Estimation: A Tool to Assess Efficacy of Treatment in Knee Osteoarthritis. MOJ Orthopedics &amp; Rheumatology 2014; 1(3): 00017.</citation>
  </reference>
  <reference>
    <citation>Stannus O, Jones G, Cicuttini F, Parameswaran V, Quinn S, Burgess J, Ding C. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010 Nov;18(11):1441-7. doi: 10.1016/j.joca.2010.08.016. Epub 2010 Sep 16.</citation>
    <PMID>20816981</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

